October 17, 2019

Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

Read More
September 17, 2019

Generium Launches First Biosimilar of Dornase Alfa; Becomes Sixth Approved Product Using Selexis SUREtechnology Platform

Read More
September 05, 2019

ZyVersa Therapeutics to Advance Development of Its Lead Inflammasome Inhibitor with Selexis and KBI Biopharma’s Integrated Development Platform

Read More

Media Downloads